Publications

Key Publications: -

Selected Original Research Papers

1. Khan A, Gajendra S, Rai S, Thakral D, Singh VK, Upadhyay AD, Bakhshi S, Seth R, Sahoo RK, Gupta R*. Leukaemic stem cell burden enhances prognostic precision in the non-adverse European LeukemiaNet risk group of acute myeloid leukaemia. Br J Haematol. 2026 Jul 11. doi: 10.1111/bjh.70679. PMID: 42433166.

2. Khan A, Gajendra S, Singh VK, Thakral D, Bakhshi S, Sahoo RK, Seth R, Rai S, Gupta R*. Single cell transcriptomics derived combinatorial markers distinguished leukemic stem cells from hematopoietic stem cells in acute myeloid leukemia. Leuk Res. 2026 Feb;161:108170. doi: 10.1016/j.leukres.2026.108170. PMID: 41579489.

3. Sharma P, Leons GK, Singh V, Naseer S, Ribeyron L, Bakhshi S, Gupta R, Gajendra S, Thoudam DS, Sarawat SK, Khan MA, Pushpam D, Sahoo RK, Roy A, Gupta SK. Gene expression signature of IKZF1 deleted B-cell acute lymphoblastic leukaemia reveals a unique regulation of MUC4. Br J Haematol. 2025 Aug 28. doi: 10.1111/bjh.70014. PMID: 40878232.

4. Gupta A, Hooda R, Motwani S, Sagar D, Aggarwal P, Abrol V, Gupta R. MuSARCyto: Multi-Head Self-Attention-Based Representation Learning for Unsupervised Clustering of Cytometry Data. Cytometry A. 2025 Aug 11. doi: 10.1002/cyto.a.24956. PMID: 40785593.

5. Ruhela V, Gupta R, Oberoi R, Gupta A. A comprehensive targeted panel of 295 genes: Unveiling key disease initiating and transformative biomarkers in multiple myeloma. Comput Biol Med. 2025;196(Pt A):110619. doi: 10.1016/j.compbiomed.2025.110619. PMID: 40617081.

6. Gajendra S, Dwivedi T, Bommannan K, Sahoo RK, Das N, Tembhare P, ---Gupta R*. Delphi Survey on Measurable Residual Disease in Multiple Myeloma: Prevailing Practices and the Way Forward in India. Clin Lymphoma Myeloma Leuk. 2025: S2152-2650(25)00180-6. doi: 10.1016/j.clml.2025.05.016. PMID: 40514308.

7. Mendiratta M, Mendiratta M, Ganguly S, Rai S, Gupta R, et al. Concurrent hypoxia and apoptosis imparts immune programming potential in mesenchymal stem cells: Lesson from acute graft-versus-host-disease model. Stem Cell Res Ther. 2024 Oct 29;15(1):381. PMID: 39468660.

8. Ma J, Xie R, Ayyadhury S, Ge C, Gupta A, Gupta R, et al. The multimodality cell segmentation challenge: toward universal solutions. Nat Methods. 2024;21(6):1103-1113. PMID: 38532015.

9. Das N, Panda D, Gajendra S, Gupta R*, et al. Immunophenotypic characterization of leukemic stem cells in acute myeloid leukemia using single tube 10-colour panel by multiparametric flow cytometry: Deciphering the spectrum, complexity and immunophenotypic heterogeneity. Int J Lab Hematol. 2024. PMID: 38456256.

10. Chatzikonstantinou T, Scarfò L, Karakatsoulis G, -----, Gupta R, et al.. Other malignancies in the history of CLL: an international multicenter study conducted by ERIC, the European Research Initiative on CLL, in HARMONY. EClinicalMedicine. 2023;65:102307. PMID: 38033506.

11. Mookerjee A, Gupta R, Kumar R, et al. Dual assessment with multiparameter flow cytometry and ¹⁸F-FDG PET/CT scan provides enhanced prediction of measurable residual disease after autologous haemopoietic stem cell transplant in myeloma-a prospective study. Bone Marrow Transplant. 2023 Sep;58(9):1045-1047. doi: 10.1038/s41409-023-02017-0. PMID: 37328681.

12. Mansouri L, Thorvaldsdottir B, Sutton LA, ---, Gupta R, et al. Different prognostic impact of recurrent gene mutations in chronic lymphocytic leukemia depending on IGHV gene somatic hypermutation status: a study by ERIC in HARMONY. Leukemia. 2023;37(2):339-347. PMID: 36566271.

13. Ruhela V, Jena L, Kaur G, Gupta R*, Gupta A. BDL-SP: A Bio-inspired DL model for the identification of altered Signaling Pathways in Multiple Myeloma using WES data. Am J Cancer Res. 2023 Apr 15;13(4):1155-1187. PMID: 37168334.

14. Thakral D, Singh VK, Gupta R*, et al. Integrated single-cell transcriptome analysis of CD34 + enriched leukemic stem cells revealed intra- and inter-patient transcriptional heterogeneity in pediatric acute myeloid leukemia. Ann Hematol. 2023;102(1):73-87. PMID: 36527458.

15. Gupta A, Gehlot S, Goswami S, Motwani S, Gupta R, et al. SegPC-2021: A challenge & dataset on segmentation of Multiple Myeloma plasma cells from microscopic images. Med Image Anal. 2023; 83:102677. doi: 10.1016/j.media.2022.102677. PMID: 36403309.

16. Das N, Dahiya M, Gupta R*, et al. Graded Depth of Response and Neoplastic Plasma Cell Index as Indicators of Survival Outcomes in Patients With Multiple Myeloma Following Autologous Stem Cell Transplant. Am J Clin Pathol. 2023 Jan 4;159(1):69-80. doi: 10.1093/ajcp/aqac129. PMID: 36317501.

17. Sagar D, Aggarwal P, Farswan A, Gupta R*, Gupta A. GCRS: A hybrid graph convolutional network for risk stratification in multiple myeloma cancer patients. Comput Biol Med. 2022; 149:106048. doi: 10.1016/j.compbiomed.2022.106048. PMID: 36113255.

18. Gupta SK, Singh M, Chandrashekar PH, Bakhshi S, Trehan A, Gupta R, et al. Clinical and Prognostic Impact of Copy Number Alterations and Associated Risk Profiles in a Cohort of Pediatric B-cell Precursor Acute Lymphoblastic Leukemia Cases Treated Under ICiCLe Protocol. Hemasphere. 2022 Sep 30;6(10):e782. doi: 10.1097/HS9.0000000000000782. PMID: 36204689

19. Ruhela V, Gupta A, Sriram K, Ahuja G, Kaur G, Gupta R*. miRPipe: A Unified Computational Framework for a Robust, Reliable, and Reproducible Identification of Novel miRNAs from the RNA Sequencing Data. Front Bioinform. 2022;2:842051. doi: 10.3389/fbinf.2022.842051. PMID: 36304305.

20. Das N, Dahiya M, Gupta R*, et al. Flow cytometric immunophenotyping of plasma cells across the spectrum of plasma cell proliferative disorders: A fresh insight with pattern-based recognition. Cytometry B Clin Cytom. 2022. doi: 10.1002/cyto.b.22062. PMID: 35212134.

21. Kumar S, Sharma A, Malik PS, Gogia A, Pathak N, Sahoo RK, Gupta R, et al. Bendamustine in combination with pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: A phase II trial. Br J Haematol. 2022 May 2. doi: 10.1111/bjh.18200. PMID: 35499209.

22. Kaur G, Jena L, Gupta R*, et al. Correlation of changes in subclonal architecture with progression in the MMRF CoMMpass study. Transl Oncol. 2022; 23:101472.PMID: 35777247.

23. Thakral D*, Gupta R*, Khan A. Leukemic Stem Cell signatures in Acute Myeloid Leukemia- Targeting the Guardians with Novel approaches. Stem Cell Reviews & Reports 2022. doi: 10.1007/s12015-022-10349-5. PMID: 35412219.

24. Gupta R*, Gehlot S, Gupta A*. C-NMC: B-Lineage Acute Lymphoblastic Leukemia: A Blood Cancer Dataset. Med Eng Phys. 2022; 103:103793. doi: 10.1016/j.medengphy.2022.103793. PMID: 35500994.

25. Das N, Dahiya M, Gupta R*, et al. Relevance of polyclonal plasma cells and post-therapy immunomodulation in MRD assessment in Multiple Myeloma. Cytometry B Clin Cytom. 2022 May;102(3):209-219. doi: 10.1002/cyto.b.22068. PMID: 35389550.

26. Farswan A, Gupta A*, Gupta R*. ARCANE-ROG: Algorithm for Reconstruction of Cancer Evolution from single-cell data using Robust Graph Learning. J Biomed Inform. 2022 Mar 22:104055. doi: 10.1016/j.jbi.2022.104055. PMID: 35337943.

27. Kumar S, Sharma A, Pramanik R, ----, Gupta R, et al. Long-Term Outcomes and Safety Trends of Autologous Stem-Cell Transplantation in Non-Hodgkin Lymphoma: A Report from a Tertiary Care Center in India. JCO Glob Oncol. 2022 May;8: e2100383. doi: 10.1200/GO.21.00383. PMID: 35561291.

28. Farswan A, Gupta A*, Jena L, Kaur G, Gupta R*. Characterizing the mutational landscape of MM and its precursor MGUS. Am J Cancer Res 2022;12(4):1919-1933. PMID: 35530275

29. Farswan A, Jena L, Kaur G, Gupta A*, Gupta R*, Rani L, Sharma A, Kumar L. Branching clonal evolution patterns predominate mutational landscape in Multiple Myeloma. Am J Cancer Res 2021; 11(11):5659-5679. PMID: 34873486; PMCID: PMC8640818

30. Farswan A, Gupta A*, Sriram K, Sharma A, Kumar L, Gupta R*. Does ethnicity matter in multiple myeloma risk prediction in the era of genomics and novel agents? Evidence from real world data. Front Oncol. 2021; 11:720932. doi: 10.3389/fonc.2021.720932. PMID: 34858811; PMCID: PMC8630746.

31. Farswan A, Gupta A, Gupta R*, et al. AI-supported modified risk staging for multiple myeloma cancer useful in real-world scenario. Transl Oncol. 2021;14(9):101157. PMID: 34247136.

32. Das N, Gupta R*, Gupta SK, et al. Critical evaluation of the utility of pre- and post-therapy immunophenotypes in assessment of measurable residual disease in B-ALL. Ann Hematol. 2021. doi: 10.1007/s00277-021-04580-2. PMID: 34236495.

33. Katiyar A, Kaur G, Rani L, Jena L, Singh H, Kumar L, Sharma A, Kaur P*, Gupta R*. Genome-wide identification of potential biomarkers in multiple myeloma using meta-analysis of mRNA and miRNA expression data. Sci Rep. 2021; 11(1):10957. PMID: 34040057.

34. Gehlot S, Gupta A*, Gupta R*. A CNN-based unified framework utilizing projection loss in unison with label noise handling for multiple Myeloma cancer diagnosis. Med Image Anal. 2021; 72:102099. doi: 10.1016/j.media.2021.102099. PMID: 34098240.

35. Goswami C, Chawla S, Thakral D, Pant H, Verma P, Malik PS, Jayadeva, Gupta R*, Ahuja G*, Sengupta D*. Molecular signature comprising 11 platelet-genes enables accurate blood-based diagnosis of NSCLC. BMC Genomics. 2020; 21(1):744. doi: 10.1186/s12864-020-07147-z. PMID: 33287695; PMCID: PMC7590669.

36. Gupta A*, Duggal R, Gehlot S, Gupta R*, et al. GCTI-SN: Geometry-inspired chemical and tissue invariant stain normalization of microscopic medical images. Med Image Anal. 2020 Jul 21; 65:101788. doi:10.1016/j.media.2020.101788. PMID: 32745978

37. Das N, Gupta R*, Gupta SK, et al. A real world-perspective of CD123 expression in acute leukemia as promising biomarker to predict treatment outcome in B-ALL and AML. Clin Lymphoma Myeloma Leuk. 2020; 20(10): e673-e684. doi: 10.1016/j.clml.2020.05.004. PMID: 32561191

38. Gehlot S, Gupta A*, Gupta R*. SDCT-AuxNetθ: DCT augmented stain deconvolutional CNN with auxiliary classifier for cancer diagnosis. Med Image Anal. 2020; 61:101661. doi: 10.1016/j.media.2020.101661. PMID: 32066066

39. Kaur G, Ruhela V, Rani L, Gupta A, Sriram K, Gogia A, Sharma A, Kumar L, Gupta R*. RNA-Seq profiling of deregulated miRs in CLL and their impact on clinical outcome. Blood Cancer J. 2020;10(1):6. doi: 10.1038/s41408-019-0272-y. (PMID:31932582)

40. Farswan A, Gupta A, Gupta R*, Kaur G. Imputation of gene expression data in blood cancer and its significance in inferring biological pathways. Front Oncol. 2020; 9:1442. doi: 10.3389/fonc.2019.01442. PMID:31970084

41. Thakral D, Kaur G, Gupta R*, et al. Rapid Identification of Key Copy Number Alterations in B- and T-Cell Acute Lymphoblastic Leukemia by Digital Multiplex Ligation-Dependent Probe Amplification. Front Oncol. 2019 Sep 13; 9:871. doi: 10.3389/fonc.2019.00871. (PMID: 31572674)

42. Mann M, Kumar S, Chauhan SS, Bhatla N, Kumar S, Bakhshi S, Gupta R, Sharma A, Kumar L.PARP-1 inhibitor modulate β-catenin signaling to enhance cisplatin sensitivity in cancer cervix. Oncotarget 2019;10(42):4262-4275. doi: 10.18632/oncotarget.27008. PMID: 31303961

43. Rani L, Gogia A, Singh V, Kumar L, Sharma A, Kaur G, Gupta R*. Comparative assessment of prognostic models in Chronic Lymphocytic Leukemia: Evaluation in Indian Cohort. Ann Hematol. 2019; 98:437-443. doi: 10.1007/s00277-018-3525-0. PMID: 30338367

44. Kaur G, Gupta R*, Mathur N, et al. Clinical impact of chromothriptic complex chromosomal rearrangements in newly diagnosed multiple myeloma. Leuk Res. 2019; 76:58-64. doi: 10.1016/j.leukres.2018.12.005. PMID: 30576858

45. Gupta R*, Kaur G, Kumar L, et al. Nucleic acid-based risk assessment and staging for clinical practice in multiple myeloma. Ann Hematol. 2018; 97(12):2447-2454. (PMID: 30056581)

46. Gupta A, Mallick P, Sharma O, Gupta R, Duggal R. PCSeg: Color model driven probabilistic multiphase level set based tool for plasma cell segmentation in multiple myeloma. PLoS One 2018; 13(12):e0207908 (PMID: 30540767)

47. Rani L, Mathur N, Gupta R*, et al. Genome-wide DNA methylation profiling integrated with gene expression profiling identifies PAX9 as a novel prognostic marker in chronic lymphocytic leukemia. Clin Epigenetics. 2017; 9:57. doi: 10.1186/s13148-017-0356-0. (PMID:28572861) 

48. Kumar L, Gogi L, Patel A, -----, Gupta R, et al. Multiple myeloma with Extra medullary disease: Impact of Autologous stem cell transplantation on outcome. Bone Marrow Transplantation 2017; 52:1473-1475 (PMID: 28805789)

49. Rani L, Mathur N, Gogia A, Vishnubhatla S, Kumar L, Sharma A, Dubey D, Kaur P, Gupta R*. Immunoglobulin Heavy Chain Variable Region Gene Repertoire and B-Cell Receptor Stereotypes in Indian Patients with Chronic Lymphocytic Leukemia. Leuk Lymphoma 2016;57(10):2389-400(PMID:26942309)

50. Kumar L, Iqbal N, Mookerjee A, Verma RK, Sharma OD, Batra A, Pramanik R, Gupta R. Complete response after autologous stem cell transplant in multiple myeloma. Cancer Med. 2014; 3:939-46. (PMID: 24777883)

51. Gupta R*, Ganeshan P, Hakim M, et al. Significantly reduced regulatory T cell population in patients with untreated multiple myeloma. Leukemia Research 2011;35: 874-878 (PMID: 21146215)

52. Agarwal P, Sekhar Das S, Gupta R, Khetan D, Chaudhary R. Quantification of Feto-Maternal Hemorrhage: Selection of Techniques for a Resource-Poor Setting. Gynecol Obstet Invest. 2010;71:47-52 (PMID: 21160194)

53. Medhi K, Raina V, Kumar L, Sharma A, Bakhshi S, Gupta R, Kumar R. Response Assessment of chronic myeloid leukemia (CML) patients receiving imatinib mesylate (Glivec) therapy: Experience from a single center in developing country. Leuk Lymphoma 2010; 51:1850-1854 (PMID: 20849386)

54. Gupta R*, Bhaskar A, Kumar L, Sharma A, Jain P. Flow cytometric immunophenotyping and minimal residual disease analysis in multiple myeloma. Am J Clin Pathol 2009;132:728-732 (PMID: 19846814)

55. Gupta R, Jain P, Deo SVS, Sharma A. Flow cytometric analysis of CD5 positive B-cells- a frame of reference for minimal residual disease in Chronic lymphocytic leukemia. Am. J Clin Path. 2004; 121:368-372 (PMID: 15023041)

56. Jain P, Kumar R, Anand M, Asthana S, Deo SVS, Gupta R, et al. Touch imprint cytology of axillary lymph nodes after neoadjuvant chemotherapy in patients with breast cancer. Cancer 2003; 99:346-351 (PMID: 14681942)